Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three antiretroviral drugs—emtricitabine, tenofovir disoproxil fumarate, and tenofovir alafenamide. All three are nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs) used in the treatment and prevention of HIV-1 infection. Emtricitabine is a cytidine analog; both tenofovir disoproxil fumarate and tenofovir alafenamide are prodrugs of the nucleotide analog reverse transcriptase inhibitor, tenofovir. These agents work by inhibiting HIV-1 reverse transcriptase, an enzyme necessary for viral replication, thereby preventing the synthesis of viral DNA from RNA templates. This triple combination is not a standard fixed-dose product but represents co-administration of these three NRTIs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on emtricitabine + tenofovir disoproxil fumarate + tenofovir alafenamide.